A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection

Journal of Viral Hepatitis

Volumn 3, Issue 4, 1996, Pages 211-215

  Main, J ^a   Brown, J L ^a   Howells, C ^a   Galassini, R ^a   Crossey, M ^a   Karayiannis, P ^a   Georgiou, P ^b   Atkinson, G ^b   Thomas, H C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Famciclovir; Hepatitis B virus; Nucleoside analogue

Indexed keywords

2 AMINOPURINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; FAMCICLOVIR; VIRUS DNA;

ADOLESCENT; ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HETEROZYGOTE; HUMAN; MALE; MIDDLE AGED; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; VIRUS REPLICATION;

2-AMINOPURINE; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CARRIER STATE; CHRONIC DISEASE; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MALE; MIDDLE AGED; VIRUS REPLICATION;

EID: 0030179646     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.1996.tb00098.x     Document Type: Article

References (21)

1. Beasley RP, Lin CC, Hwang LY, Chien CS. Hepatocellular carcinoma and hepatitis B virus. Lancet 1981; ii: 1129-1131.
2. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10: 761-763.
3. Lai CL, Lok ASF, Lin HJ et al. Placebo-controlled trial of recombinant alfa2 interferon (rIFN) in Chinese HBsAg carrier children. Lancet 1987; ii: 877-880.
4. Hadziyannis S, Bramou T, Makris A, Moussoulis G, Zignego L, Papaioannou C. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. J Hepatol 1990; 11:S133-136.
5. Pue MA, Benet LZ. Pharmacokinetics of famciclovir in man. Antiviral Chem Chemother 1993; 4 (suppl 1): 47-55.
6. Tsiquaye KN. Famciclovir (FCV) prophylaxis of acute duck hepatitis B virus (DHBV) infection in Pekin ducklings. Proc 8th Triennial Congress; Int Symp Viral Hep Liver Dis, Tokyo, May 1993.
7. Tsiquaye KN, Slomka MJ, Maung M. Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo. J Med Virol 1994; 42: 306-310.
8. Korba BE, Boyd MR. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells (in press).
9. Boker KH, Ringe B, Kruger M, Pichlmayr R, Manns MP. Prostaglandin E plus famciclovir - a new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation 1994; 57: 1706-1708.
10. Weller IVD, Fowler MJ, Monjardino J, Thomas HC. The detection of HBV-DNA in serum by molecular hybridisation; a more sensitive method for the detection of complete HBV particles. J Med Virol 1982; 9: 273-280.
11. Tsiquaye K, Sutton D, Maung M et al. Pharmacokinetics and antiviral activities of penciclovir and famciclovir in Pekin ducks chronically infected with duck hepatitis B virus. Proc Intersci Conf Antimicrob Agents Chemother 1993; Abstr 1594.
12. Korba BE, Milman G. A cell culture assay for compounds which inhibit hepatitis B virus replication. Antivir Res 1991; 15: 217-228.
13. Vere Hodge RA, Sutton D, Boyd MR, Harnden MR, Jarvest RL. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine; penciclovir]. Antimicrob Agents Chemother 1989; 33: 1765-1773.
14. Earnshaw DL, Bacon TH, Dalison SJ, Edmonds K, Perkins RM, Vere Hodge RA. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex type 1 (HSV 1), HSV2 and varicella-zoster virus. Antimicrob Agents Chemother 1992; 36: 2747-2757.
15. Zoulim E, Dannaoui E, Trepo C. Inhibitory effect of penciclovir on the priming of hepadnavirus reverse transcriptase. Proc 35th Intersci Conf Antimicrob Agents Chemother 1995; H43.
16. Garcia G, Smith CI, Weissberg JI et al. Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B. Ann Intern Med 1987; 107: 278-285.
17. Weller IVD, Carreno V, Fowler MJF et al. Acyclovir inhibits hepatitis B viral replication in man. Lancet 1982; i: 273.
18. McKenzie R, Fried MW, Sallie R et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333: 1099-1105.
19. Tyrrell DLJ, Mitchell MC, De Man RA et al. Phase II trial of lamivudine for chronic hepatitis B. Hepatology (suppl) 1993; 18: 112A.
20. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-1661.
21. Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimocrob Agents Chemother 1994; 38: 2454-2457.